drugset / Trial / NCT04502381
Combined Inhalational With Intravenous Amphotericin B Versus Intravenous Amphotericin B Alone for Pulmonary Mucormycosis
RandomizedParallel-groupOpen-labelTreatment
Summary
To assess the safety and feasibility of combined inhalational and intravenous amphotericin B therapy for the treatment of pulmonary mucormycosis. And compare the efficacy of combined therapy with that of intravenous amphotericin B alone.
Timeline
- Start
- 2020-07-01
- Primary completion
- 2021-10-30
- Completion
- 2021-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amphotericin B | Unknown | 5 mg/kg | Inhaled |
| Subject | Amphotericin B | Unknown | 10 mg | Inhaled |